Ropes and Gray: Vor Bio Expands RemGen Collaboration and Licenses Next-Generation Autoimmune Drug for Up to $356 Million
November 17, 2026
November 17, 2026
BOSTON, Massachusetts, Nov. 17 -- Ropes and Gray, a law firm, posted the following news:
* * *
Vor Bio Expands RemGen Collaboration and Licenses Next-Generation Autoimmune Drug for up to $356 Million
November 16, 2026
Ropes & Gray advised Vor Bio in an amendment to its existing agreement with China biotechnology company RemeGen for its next-generation autoimmune drug, RC298, in a deal worth up to $356 million that was announced on November . . .
* * *
Vor Bio Expands RemGen Collaboration and Licenses Next-Generation Autoimmune Drug for up to $356 Million
November 16, 2026
Ropes & Gray advised Vor Bio in an amendment to its existing agreement with China biotechnology company RemeGen for its next-generation autoimmune drug, RC298, in a deal worth up to $356 million that was announced on November . . .
